Ultragenyx Pharmaceutical Inc (RARE)
41.56
-0.40
(-0.95%)
USD |
NASDAQ |
May 08, 16:00
41.55
-0.01
(-0.02%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly): 178.49M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 178.49M |
| December 31, 2023 | 160.56M |
| September 30, 2023 | 157.24M |
| June 30, 2023 | 164.95M |
| March 31, 2023 | 165.70M |
| December 31, 2022 | 170.81M |
| September 30, 2022 | 237.30M |
| June 30, 2022 | 154.53M |
| March 31, 2022 | 143.16M |
| December 31, 2021 | 123.01M |
| September 30, 2021 | 113.42M |
| June 30, 2021 | 113.20M |
| March 31, 2021 | 147.52M |
| December 31, 2020 | 131.10M |
| September 30, 2020 | 87.31M |
| June 30, 2020 | 80.71M |
| March 31, 2020 | 112.96M |
| December 31, 2019 | 83.06M |
| September 30, 2019 | 100.14M |
| June 30, 2019 | 96.04M |
| March 31, 2019 | 78.10M |
| December 31, 2018 | 71.62M |
| September 30, 2018 | 70.04M |
| Date | Value |
|---|---|
| June 30, 2018 | 76.84M |
| March 31, 2018 | 75.50M |
| December 31, 2017 | 61.53M |
| September 30, 2017 | 60.41M |
| June 30, 2017 | 58.44M |
| March 31, 2017 | 51.27M |
| December 31, 2016 | 50.75M |
| September 30, 2016 | 48.71M |
| June 30, 2016 | 43.33M |
| March 31, 2016 | 40.42M |
| December 31, 2015 | 44.56M |
| September 30, 2015 | 29.70M |
| June 30, 2015 | 23.10M |
| March 31, 2015 | 17.36M |
| December 31, 2014 | 13.52M |
| September 30, 2014 | 12.85M |
| June 30, 2014 | 11.24M |
| March 31, 2014 | 8.353M |
| December 31, 2013 | 8.204M |
| September 30, 2013 | 6.762M |
| June 30, 2013 | 7.199M |
| March 31, 2013 | 5.664M |
| December 31, 2012 | 3.775M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
80.71M
Minimum
Jun 2020
237.30M
Maximum
Sep 2022
136.06M
Average
137.13M
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 58.50M |
| Madrigal Pharmaceuticals Inc | 70.64M |
| Sarepta Therapeutics Inc | 200.40M |
| FibroGen Inc | 51.70M |
| Rocket Pharmaceuticals Inc | 45.23M |